A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs BB-401 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Benitec Biopharma
- 20 May 2018 Status changed from active, no longer recruiting to recruiting.
- 16 May 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 16 Feb 2018 New trial record